ABL1 and melanoma: Since MEK/ERK reactivation during resistance induces MYC (a convergent point in multiple resistance pathways)28, which is efficiently blocked by targeting ABL1/2, and ABL1 mRNA is upregulated during resistance in primary melanomas, we examined the clinical significance of our findings by testing whether ABL1 and MYC expression are linked in patient samples.